BioSpace News Archive

A large complex sigmoid polyp in a 62-year-old male patient was successfully removed in a 60-minute procedure without surgical intervention using DiLumen C2, a second-generation endoscopic dual balloon colon stabilization accessory that employs two 6mm working channels that accommodate several flexible therapeutic instruments designed to efficiently retract and dissect tissue.

Company to Make Donation to Establish Pain Management Education Foundation

Theratechnologies Inc. (“Theratechnologies” or the “Company”) (NASDAQ: THTX) (TSX: TH), a commercial-stage pharmaceutical company addressing unmet medical needs for people with orphan medical conditions, including those living with HIV, is pleased to provide details about the webcast of its R&D Day.

Accuray Incorporated (Nasdaq: ARAY) announced today that Suzanne Winter has joined the company as Senior Vice President, Chief Commercial Officer effective October 21, 2019

PRP a Potential Method for Reducing Recurrence After Drug Treatment Failures Global Metastatic Cancer Treatment Market Anticipated to Reach $98.24 Billion By 2025

Halloran Consulting Group, a life science regulatory, quality and clinical consulting firm, announced the launch of its Speaker Series, an interactive speaking circuit featuring Halloran’s most experienced strategic thinkers.

Dr. Martin has previously served as the company’s president and chief operating officer, as well as its chief scientific officer.

Golden Leaf Holdings, (CSE: GLH) (OTCQB: GLDFF) (“Golden Leaf” or the “Company”), a pioneering cannabis company with cultivation, production and retail built around recognized brands, announced the appointment of Jane Sullivan to the newly created role of Chief People Officer

The 2020 C3 US-Arab Healthcare Summit is honored to announce Her Royal Highness Princess Dina Mired of Jordan as their 2020 Keynote Speaker and recipient of the prestigious C3 Summit Women’s Empowerment Award.

Upon closing of the transaction, Casebia Therapeutics would focus on the development of its lead programs in hemophilia, ophthalmology and autoimmune diseases, with Bayer having opt-in rights for two products at IND submission.